Fluidigm Corporation and SABiosciences (a QIAGEN Company) today
announced that they have teamed up to create over 100 pathway-focused
gene expression panels validated for real-time PCR analysis on the
Fluidigm BioMark™ System for Genetic Analysis. These kits are named the
RT² Profiler™ PCR Arrays for the Fluidigm BioMark system.
“SABiosciences offers real-time PCR Arrays that are the most reliable
and sensitive gene expression profiling technology for analyzing a
focused panel of genes and now gain the additional benefits of
Fluidigm’s genetic analysis technology”
These gene expression assays are specifically designed for the workflow
of Fluidigm’s integrated fluidic circuits (IFCs) and the BioMark system.
Each reagent kit includes pre-aliquoted reagents and primers needed for
synthesizing first-strand cDNA ready for preamplification and
pathway-focused analysis. PCR Arrays contain enough reagent to run five
96.96 Dynamic Array chips (customized panels are also available). PCR
arrays come in a 96-well format making either 96.96 or 48.48 Dynamic
Array™ chip set up fast, simple and affordable.
“SABiosciences solutions focusing on the analysis of pathways with real
time assay panel kits are an excellent fit to our products. The kits
include 96 cataloged gene expression assays, targeting genes in signal
transduction, biological process, and disease-related pathways. The kits
can provide a great solution for customers looking to lower start up
costs, or that need pre-validated pathways for a new project,” said Mike
Lee, Fluidigm’s Senior Director of Marketing.
“SABiosciences offers real-time PCR Arrays that are the most reliable
and sensitive gene expression profiling technology for analyzing a
focused panel of genes and now gain the additional benefits of
Fluidigm’s genetic analysis technology,” said Shankar Sellappan, Ph.D.,
SABiosciences PCR Array Product Manager.
Investigational gene therapy shows promise for rare childhood neurodegenerative disease